ZymoGenetics presents positive results on RECOTHROM Thrombin
ZymoGenetics Inc. has presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM™ Thrombin, a topical (Recombinant) administered by spray device to burn wound excision sites. The study revealed that the topical application of RECOTHROM using a pump spray device was well tolerated and it demonstrated a similar safety profile and rate of antibody formation to that observed in the rThrombin Phase 3 clinical trial.
- AmStem Reports Positive Early Results From SteMixxTM Consumer Study
- NanoVibronix Presents Its Second Generation PainShield For The Treatment Of Pain And Wounds
- European Medicines Agency Confirms Positive Benefit-Risk Balance Of Topical Formulations Of Ketoprofen
- People opting for cost-effective version of face lift
